Infected Cell Carriers: A New Strategy for Systemic Delivery of Oncolytic Measles Viruses in Cancer Virotherapy
Open Access
- 1 January 2007
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 15 (1), 114-122
- https://doi.org/10.1038/sj.mt.6300020
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cellsBlood, 2005
- Oncolytic measles viruses for cancer therapyExpert Opinion on Biological Therapy, 2004
- Oncolytic viral therapiesCancer Gene Therapy, 2004
- Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporterBlood, 2004
- Structure and function of a paramyxovirus fusion proteinBiochimica et Biophysica Acta (BBA) - Biomembranes, 2003
- Neutralizing B Cell Response in MeaslesViral Immunology, 2002
- Systemic therapy of myeloma xenografts by an attenuated measles virusBlood, 2001
- Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient miceBlood, 2001
- SLAM (CDw150) is a cellular receptor for measles virusNature, 2000
- The human CD46 molecule is a receptor for measles virus (Edmonston strain)Cell, 1993